Showing results (51-60 of 783) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|August 27, 2016
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial
The Lancet. HIV|August 27, 2016
Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling studyJessica B McGillen, Sarah-Jane Anderson, Mark R Dybul, et al.
The Lancet. HIV|May 15, 2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
The Lancet. HIV|September 24, 2016
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trialSteffen Leth, Mariane H Schleimann, Sara K Nissen, et al.
The Lancet. HIV|September 24, 2016
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort studyMonica Gandhi, David V Glidden, Kenneth Mayer, et al.
The Lancet. HIV|September 24, 2016
Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta-analysisJennifer Cohn, Katherine Whitehouse, Julia Tuttle, et al.
The Lancet. HIV|April 13, 2018
The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trialThomas A Rasmussen, James H McMahon, J Judy Chang, et al.
The Lancet. HIV|May 9, 2017
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort studyJemma O'Connor, Colette Smith, Fiona C Lampe, et al.
The Lancet. HIV|July 13, 2018
Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedingsKathleen R Page, Suzanne Dolwick Grieb, Karen Nieves-Lugo, et al.
The Lancet. HIV|June 22, 2018
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialEric S Daar, Edwin DeJesus, Peter Ruane, et al.
Pageof 79